IP : Genomics plc - Signs Collaboration Agreement with Biogen

Genomics' proprietary statistical analysis tools and integrated multi-phenotype database will be used to inform Biogen's drug research and development processes

Genomics plc ('Genomics'), a leading analysis company developing algorithms, data resources, and software solutions to uncover the relationships between genetic variation and human disease, today announced that it has entered into a collaboration agreement with Biogen. The collaboration aims to refine drug target selection through the use of sophisticated analysis of human genetic data.

Under the terms of the agreement Biogen will leverage findings from Genomics' integrated database and state-of-the-art analysis tools, which will be used to guide drug research and development. Biogen will use these findings to help answer questions regarding the likely efficacy and safety of their intended drug targets.

Genomics has developed a unique analytical platform for genomic data analysis and interpretation. The platform combines proprietary algorithms and software with the Company's integrated genome-phenome database and analytical expertise to uncover the relationships between genetic variation and human health outcomes. Genomics has several existing partnerships with large pharmaceutical companies, and in clinical genomics is a platform partner for Genomics England, the company undertaking the 100,000 Genomes project in the UK.

John Colenutt, CEO, Genomics plc, said: 'This agreement highlights the growing commitment within the pharmaceutical and biotech industries to systematically use human genetic data in research to increase the chance of success in drug development. With our proprietary technology, integrated database and tools, Genomics is ideally positioned to support pharma and biotech companies in this area.'

Sally John, Vice President, Computational Biology and Genomics, Biogen, said: 'At Biogen we firmly believe that genetic information can be a powerful tool in assessing potential drug targets. We are delighted to collaborate with the world-leading analysts at Genomics, and to benefit from their unique integrated genome-phenome database.'

END
For further information please contact:
Zyme Communications
Lorna Cuddon
Tel: +44 (0)7811996942
Email: lorna.cuddon@zymecommunications.com

About Genomics plc http://www.genomicsplc.com/
Genomics was founded by four leading Oxford academics, including Professor Peter Donnelly, Director of The Wellcome Trust Centre for Human Genetics, and Professor Gil McVean, Director of The Big Data Institute. The Company has developed a unique platform for genomic sequence data analysis and interpretation which combines world-leading expertise in statistical analysis and data mining with a unique integrated database linking genotypes and phenotypes. Genomics England, the company running the UK project to undertake whole genome sequencing of 100,000 patients in the National Health Service, has appointed Genomics plc as a Platform Provider and has also awarded the Company three SBRI grants. Genomics plc is also working with three major pharmaceutical companies to bring the benefits of genomic analysis to their drug development processes. The Company is supported by major investors, including IP Group, Invesco Perpetual, Woodford Investment Management and Lansdowne Partners.